Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Nasdaq Biotechnology

109.77
+0.17880.16%
Post-market: 110.480.7032+0.64%19:30 EDT
Volume:14.72K
Turnover:1.63M
Market Cap:95.50M
PE:- -
High:112.13
Open:112.13
Low:109.77
Close:109.60
52wk High:126.40
52wk Low:55.34
Shares:870.00K
Float Shares:870.00K
Volume Ratio:1.17
T/O Rate:1.69%
Dividend:0.32
Dividend Rate:0.29%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Vertex (VRTX) Stock Looks Reasonable As Growth Must Justify Its Run

Simply Wall St.
·
Sep 01

Trump Administration Announces Drug Pricing Deals with CSL, Astellas and Others

Reuters
·
Sep 01

Political and General News Events from August 31

Reuters
·
Aug 31

Amgen Says Repatha Cuts Death Risk 20% in High-Risk Patients

MT Newswires Live
·
Aug 31

Amgen Repatha reduces risk of death in high-risk adults for first heart attack

TIPRANKS
·
Aug 31

Amgen's Repatha® Reduces Risk of Death in Patients at High Risk for a First Heart Attack or Stroke

THOMSON REUTERS
·
Aug 31

Gilead (GILD) Stock Stays Cheap After A 143% Five Year Run

Simply Wall St.
·
Aug 30

Crinetics Shareholders Approve Vertex Acquisition at Special Meeting

TIPRANKS
·
Aug 29

Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

Amgen Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

Gilead Sciences Stock (GILD) Slips 2% Despite FDA Approval of Bixlenvo

TIPRANKS
·
Aug 29

Vertex Tests VX-407’s Impact on Birth Control: What It Means for VRTX Investors

TIPRANKS
·
Aug 29

Amgen’s Pediatric Psoriasis Study Wrap-Up: What Apremilast Safety Data Means for Investors

TIPRANKS
·
Aug 29

Political and General News Events from August 28

Reuters
·
Aug 28

Gilead Breaks Ground on Foster City Biologics Facility in $32 Billion US Investment Push

Reuters
·
Aug 28

Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares

Reuters
·
Aug 28

Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV

TIPRANKS
·
Aug 28

US FDA Approves Gilead's Once-Daily Combination Pill for HIV Treatment

Reuters
·
Aug 28

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens

THOMSON REUTERS
·
Aug 28

Moderna Inc. Stock Slips 4.6%, Underperforms Peers

Dow Jones
·
Aug 28